Zomig-ZMT en es it fr

Zomig-ZMT Brand names, Zomig-ZMT Analogs

Zomig-ZMT Brand Names Mixture

  • No information avaliable

Zomig-ZMT Chemical_Formula


Zomig-ZMT RX_link


Zomig-ZMT fda sheet


Zomig-ZMT msds (material safety sheet)

Zomig-ZMT Synthesis Reference

No information avaliable

Zomig-ZMT Molecular Weight

287.357 g/mol

Zomig-ZMT Melting Point

No information avaliable

Zomig-ZMT H2O Solubility

No information avaliable

Zomig-ZMT State


Zomig-ZMT LogP


Zomig-ZMT Dosage Forms

Spray; Tablet

Zomig-ZMT Indication

For the acute treatment of adult migraine (with or without auras)

Zomig-ZMT Pharmacology

Zolmitriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Zolmitriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.

Zomig-ZMT Absorption


Zomig-ZMT side effects and Toxicity

No information avaliable

Zomig-ZMT Patient Information

No information avaliable

Zomig-ZMT Organisms Affected

Humans and other mammals